KalVista Pharmaceuticals Files 8-K

TL;DR

KalVista dropped an 8-K, looks like new financial stuff and disclosures.

AI Summary

On November 4, 2024, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant, and includes Regulation FD Disclosure and Financial Statements and Exhibits.

Why It Matters

This 8-K filing signals significant corporate actions, including potential new financial obligations and regulatory disclosures, which could impact investors' understanding of the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can lead to stock price volatility, especially when related to definitive agreements or financial obligations.

Key Numbers

• 001-36830 — SEC File Number (Identifier for KalVista's filings)
• 20-091 — IRS Number (Tax identification number for the company)

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — Registrant
• November 4, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Carbylan Therapeutics, Inc. (company) — Former company name
• Carbylan Biosurgery, Inc (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
• $100.0 million — bsidiary received an upfront payment of $100.0 million (the "Initial Amount") in exchange for
• $500.0 million — on annual net sales up to and including $500.0 million (the "First Tier Royalty Rate"); 1.10%
• $750.0 million — $500.0 million and up to and including $750.0 million; and 0.25% on annual net sales above $7
• $550.0 million — t achieves annual net sales of at least $550.0 million in any calendar year ending before Janu
• $50.0 million — earn a sales-based milestone payment of $50.0 million (the "Sales-Based Milestone Payment").
• $22.0 million — ect to receive an additional payment of $22.0 million in cash (the "Optional Payment" and, to
• $57.0 million — will be increased from $50.0 million to $57.0 million. Under the PSA, the Subsidiary has th

Filing Documents

• d904891d8k.htm (8-K) — 35KB
• d904891dex991.htm (EX-99.1) — 13KB
• 0001193125-24-250223.txt ( ) — 179KB
• kalv-20241104.xsd (EX-101.SCH) — 3KB
• kalv-20241104_lab.xml (EX-101.LAB) — 18KB
• kalv-20241104_pre.xml (EX-101.PRE) — 11KB
• d904891d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release issued November 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

Forward-Looking Statements This filing contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and potential amount of milestones and royalty payments to be received under the PSA. Statements including words such as "may," "will," "to be," or "expect" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including the risk that sebetralstat may not be approved by the FDA for the treatment of HAE on or prior to September 30, 2025, or at all, and risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the SEC. These forward-looking statements speak only as of the date of this report, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: November 4, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR